Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, Daniel M. Muldoon, Hira Rizvi, Arielle Elkrief, Jia Luo, Joao V. Alessi, Federica Pecci, Giuseppe Lamberti, Alessandro Di Federico, Lingzhi Hong, Jianjun Zhang, John V. Heymach, Don L. Gibbons, Andrew J. Plodkowski, Vignesh Ravichandran, Mark T.a. Donoghue, Chad Vanderbilt, Marc Ladanyi, Charles M. Rudin, Mark G. Kris, Gregory J. Riely, Jamie E. Chaft, Matthew D. Hellmann, Natalie I. Vokes, Mark M. Awad, Adam J. SchoenfeldClinical 2023 · DOI

Abstract

Among patients with advanced NSCLC treated with ICIs, distinct features including high TMB, nonsquamous histology, and depth of radiographic improvement distinguish patients poised to achieve LTR compared with initial response followed by progression, whereas high PD-L1 does not.
BibTeX
@inproceedings{thummalapalli2023clinical,
  author = {Rohit Thummalapalli and Biagio Ricciuti and Chaitanya Bandlamudi and Daniel M. Muldoon and Hira Rizvi and Arielle Elkrief and Jia Luo and Joao V. Alessi and Federica Pecci and Giuseppe Lamberti and Alessandro Di Federico and Lingzhi Hong and Jianjun Zhang and John V. Heymach and Don L. Gibbons and Andrew J. Plodkowski and Vignesh Ravichandran and Mark T.A. Donoghue and Chad Vanderbilt and Marc Ladanyi and Charles M. Rudin and Mark G. Kris and Gregory J. Riely and Jamie E. Chaft and Matthew D. Hellmann and Natalie I. Vokes and Mark M. Awad and Adam J. Schoenfeld},
  title = {{Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer}},
  booktitle = {Clinical},
  year = {2023},
  doi = {10.1158/1078-0432.ccr-23-1207},
}

Loading related content...

Figure